Home › Follicular Lymphoma › California
Follicular Lymphoma clinical trials in California
36 studies for Follicular Lymphoma are looking for participants at sites in California.
Cities in California
- Baldwin Park16 studies
- Los Angeles13 studies
- San Diego8 studies
- San Francisco8 studies
- Mountain View7 studies
- Irvine5 studies
- Orange5 studies
- Santa Monica3 studies
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Cedar Sinai Cancer Center ( Site 0119), Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07519772A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- City of Hope - Duarte Cancer Center ( Site 1301), Duarte
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07634471A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
- Stanford, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06510361A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- David Geffen School of Medicine at UCLA, Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06091254A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- David Geffen School of Medicine at UCLA, Los Angeles
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06149286A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- City of Hope, Duarte
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
- University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07226843Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Kaiser Permanente-Anaheim, Anaheim
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- Kaiser Permanente-Bellflower, Bellflower
- and 25 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Nov 3, 2026 · NCT07215910A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound
- University of California Irvine Medical Center, Orange
RecruitingPhase 4
Ages 18 and older · Women · Updated Nov 2, 2026 · NCT07167862Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06815029Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06860594A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Research Site, Clovis
- Research Site, Los Alamitos
- Research Site, San Diego
- and 1 more
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 21, 2026 · NCT06549595SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of California San Diego, La Jolla
- University of California, Los Angeles, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07424833Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06526793A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
- Community Health Project Los Angeles (CHPLA), Los Angeles
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07631598A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06453044NEO100 and High-Grade Meningioma
- University of Southern California, Los Angeles
- Sutter Health Research Institute, San Francisco
- Saint John Cancer Institute, Santa Monica
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT05023018Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Interventions in Mathematics and Cognitive Skills
- Stanford Cognitive and Systems Neuroscience Laboratory, Palo Alto
RecruitingHealthy volunteers welcome
Ages 6 to 12 · All sexes · Updated Aug 11, 2026 · NCT05201534STimulation to Activate RespIration
- University of California San Diego, La Jolla
Recruiting
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06832306This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- City of Hope Comprehensive Cancer Center, Duarte
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06911502Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Stanford Cancer Center, Palo Alto
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 22, 2024 · NCT05255354From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.